Dr. David Israeli is the Chairman & CEO of Magenta Medical, a clinical-stage start-up company developing innovative therapies for the treatment of acute heart- failure. Based on its proprietary blood pump technology, Magenta is currently in clinical trials with its first product to unload the kidneys and in development of its second product to unload the left ventricle of the heart. Previously, David was a life sciences General Partner at Pitango Venture Capital, one of the leading VC groups in Israel, where he led investments in the areas of medical devices and digital health.

Before joining Pitango, David was the Director of Business Development and Marketing at Medtronic Ventor Technologies, following Medtronic’s acquisition of Ventor Technologies for $325M in early 2009.

Prior to this, David spent several years in the United States. After complementing his medical training with a Master of Business Administration, he joined Medtronic and filled roles ranging from corporate development and M&A to business and market development. David then went on to become the VP of Medical Affairs at Rhythmia Medical, where he led the pre-clinical and clinical activities of the company. Rhythmia developed an innovative system to perform real-time 3D electro-anatomical mapping of the heart and it was subsequently acquired by Boston Scientific in October 2012.

David holds an MD from the Hebrew University of Jerusalem and an MBA from the Harvard Business School.